Detalles de la búsqueda
1.
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Breast Cancer Res Treat
; 180(3): 647-655, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32060783
2.
A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers.
Cancer Invest
; 34(5): 213-9, 2016 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-27127841
3.
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
Breast Cancer Res Treat
; 154(2): 299-308, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26507191
4.
Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer.
Breast Cancer Res Treat
; 152(3): 557-67, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26155975
5.
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Breast Cancer Res Treat
; 154(1): 89-97, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26456573
6.
Patient perspectives on breast cancer treatment plan and summary documents in community oncology care: a pilot program.
Cancer
; 119(1): 164-72, 2013 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23197335
7.
Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors.
Cancer Invest
; 30(6): 481-6, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22536933
8.
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Clin Breast Cancer
; 22(3): 269-278, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34824002
9.
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
Clin Adv Hematol Oncol
; 9(4): 280-6, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21558987
10.
A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Breast Cancer Res Treat
; 123(2): 471-5, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20658263
11.
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
Clin Breast Cancer
; 8(3): 242-8, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18650154
12.
Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
J Oncol Pract
; 10(1): 68-74, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24065402
13.
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.
J Clin Oncol
; 28(1): 43-8, 2010 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19901100
14.
A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Clin Breast Cancer
; 10(3): 217-23, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20497920
15.
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
J Clin Oncol
; 26(20): 3317-23, 2008 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-18490651
Resultados
1 -
15
de 15
1
Próxima >
>>